KTRA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 04:00):

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients...

Stats
今日成交量	3.42M
平均成交量	14.85M
市值	8.69M
EPS	$0 ( 2024-02-13 )
下一个收益日期	( $-0.250 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-30	Johnson Laura L.	Buy	8 500	Options (Right to Buy)
2023-08-30	Favorito Tamara A	Buy	8 500	Options (Right to Buy)
2023-08-30	Hoffman Robert E.	Buy	23 142	Options (Right to Buy)
2023-08-30	Toth Robert Joseph Jr	Buy	8 500	Options (Right to Buy)
2023-08-30	Brown Dennis M	Buy	10 175	Options (Right to Buy)

INSIDER POWER
100.00
Last 96 transactions
Buy: 12 848 509 \| Sell: 15 566

音量相关性

長: 0.02 (neutral)

短: 0.58 (weak)

Signal:(49.171) Neutral

Kintara Therapeutics, 相关性

10 最正相关
CRON	0.925
EVLO	0.918
RPTX	0.904
SLNG	0.901
CFRX	0.899
DRUG	0.898
LVTX	0.897
JAGX	0.895
REYN	0.894
KNSA	0.894

10 最负相关
CSLM	-0.923
HERA	-0.911
TBSAU	-0.91
CITE	-0.909
PPYA	-0.906
HERAU	-0.903
FRON	-0.903
ABGI	-0.903
FTAA	-0.901
BYNOU	-0.901

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kintara Therapeutics, 相关性 - 货币/商品

0.00
( neutral )

-0.64
( weak negative )

0.00
( neutral )

0.57
( weak )

Kintara Therapeutics, 财务报表

Annual	2023
营收:	$0
毛利润:	$-60 000.00 (0.00 %)
EPS:	$-9.04

FY	2023
营收:	$0
毛利润:	$-60 000.00 (0.00 %)
EPS:	$-9.04

FY	2022
营收:	$0
毛利润:	$-60 000.00 (0.00 %)
EPS:	$-23.22

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-73.97

Financial Reports:

No articles found.

Kintara Therapeutics,

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.